1. Home
  2. TDS vs AKRO Comparison

TDS vs AKRO Comparison

Compare TDS & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TDS
  • AKRO
  • Stock Information
  • Founded
  • TDS 1968
  • AKRO 2017
  • Country
  • TDS United States
  • AKRO United States
  • Employees
  • TDS N/A
  • AKRO N/A
  • Industry
  • TDS Telecommunications Equipment
  • AKRO Biotechnology: Pharmaceutical Preparations
  • Sector
  • TDS Telecommunications
  • AKRO Health Care
  • Exchange
  • TDS Nasdaq
  • AKRO Nasdaq
  • Market Cap
  • TDS 3.9B
  • AKRO 3.9B
  • IPO Year
  • TDS N/A
  • AKRO 2019
  • Fundamental
  • Price
  • TDS $40.37
  • AKRO $51.69
  • Analyst Decision
  • TDS Buy
  • AKRO Strong Buy
  • Analyst Count
  • TDS 2
  • AKRO 6
  • Target Price
  • TDS $50.00
  • AKRO $82.50
  • AVG Volume (30 Days)
  • TDS 1.1M
  • AKRO 1.6M
  • Earning Date
  • TDS 08-01-2025
  • AKRO 08-08-2025
  • Dividend Yield
  • TDS 0.41%
  • AKRO N/A
  • EPS Growth
  • TDS N/A
  • AKRO N/A
  • EPS
  • TDS N/A
  • AKRO N/A
  • Revenue
  • TDS $4,856,000,000.00
  • AKRO N/A
  • Revenue This Year
  • TDS N/A
  • AKRO N/A
  • Revenue Next Year
  • TDS $0.40
  • AKRO N/A
  • P/E Ratio
  • TDS N/A
  • AKRO N/A
  • Revenue Growth
  • TDS N/A
  • AKRO N/A
  • 52 Week Low
  • TDS $17.90
  • AKRO $21.34
  • 52 Week High
  • TDS $41.21
  • AKRO $58.40
  • Technical
  • Relative Strength Index (RSI)
  • TDS 71.49
  • AKRO 45.35
  • Support Level
  • TDS $34.94
  • AKRO $50.13
  • Resistance Level
  • TDS $35.86
  • AKRO $53.60
  • Average True Range (ATR)
  • TDS 1.28
  • AKRO 2.03
  • MACD
  • TDS 0.49
  • AKRO -0.83
  • Stochastic Oscillator
  • TDS 96.55
  • AKRO 6.37

About TDS Telephone and Data Systems Inc.

Telephone and Data Systems Inc is a diversified telecommunications operator that provides mobile, telephone, and broadband services. The company's segments include UScellular Wireless, UScellular Towers, and TDS Telecom. It generates maximum revenue from the UScellular Wireless segment.

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Share on Social Networks: